Results 141 to 150 of about 20,878 (216)

Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study [PDF]

Wenhua Wang, Bingyi Wang, Yifei Sun, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Zheng Song, Wei Li, Lanfang Li, Xianhuo Wang, Huilai Zhang   +10 more
openalex   +1 more source

Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study [PDF]

, 2017
Jan de Jong, Peter Hellemans, James Jiao, Yuhan Huang, Sofie Mesens, Juthamas Sukbuntherng, Danièle Ouellet   +6 more
openalex   +1 more source

Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind? [PDF]

Eur Cardiol
Esposito R, Menna P, Salvatorelli E, Camilli M, Minotti G.   +4 more
europepmc   +1 more source

Supplemental Tables 1-5 from Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

, 2023
Fabiola Cervantes-Gomez, Betty Lamothe, Jennifer A. Woyach, William G. Wierda, Michael J. Keating, Kumudha Balakrishnan, Varsha Gandhi   +6 more
openalex   +1 more source

Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain. [PDF]

Ther Adv Hematol
Fernández de Larrea C, Loscertales J, Cabañas V, Freiria C, Blanchard MJ, Askari E, Lorenzo Pérez M, Abril L, López Pardo J, Pinzón S, Díaz Gálvez J, Amer N, Ramírez Páyer Á, García Sánchez R, Alcalá MM, Capote FJ, Moreno D, Bolumburu C, Rubio-Azpeitia E, García Sanz R.   +19 more
europepmc   +1 more source

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial. [PDF]

Lancet
Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerlöf I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S, ENRICH investigators.   +30 more
europepmc   +1 more source

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib [PDF]

, 2017
Allison Winter, Daniel J. Landsburg, Anthony R. Mato, Krista M. Isaac, Francisco J. Hernandez‐Ilizaliturri, Nishitha Reddy, Stephen D. Smith, Mazyar Shadman, Mitchell R. Smith, Paolo Caimi, Deepa Jagadeesh, Brian T. Hill   +11 more
openalex   +1 more source

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

, 2014
Fabio Da Roit, Patrick Engelberts, Ronald P. Taylor, Esther C.W. Breij, Giuseppe Gritti, Alessandro Rambaldi, Martino Introna, Paul W.H.I. Parren, Frank J. Beurskens, Josée Golay   +9 more
openalex   +2 more sources

Ibrutinib increases miR-181a/b in leukemic cells from patients with chronic lymphocytic leukemia. [PDF]

Blood Adv
Ramassone A, Pagotto S, Di Marco M, Rashid MM, Di Camillo C, Palmiero F, Innocenti I, Autore F, Tomasso A, Laurenti L, Visone R.   +10 more
europepmc   +1 more source

Real-World Treatment Patterns and Outcomes of Zanubrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (CLL/SLL). [PDF]

Cancer Med
Krackeler ML, Chee BH, Orchanian AK, Liu R, Law L, Zhu S, Zhu Z, Sakoda LC, Buchanan S, Massoudi M, Lopez A, Tavakoli J.   +11 more
europepmc   +1 more source